Search

Your search keyword '"DRUG development"' showing total 41,403 results

Search Constraints

Start Over You searched for: Descriptor "DRUG development" Remove constraint Descriptor: "DRUG development" Language english Remove constraint Language: english
41,403 results on '"DRUG development"'

Search Results

1. Sequence-dependent model of allosteric communication.

2. Phytotherapeutic potential against MRSA: mechanisms, synergy, and therapeutic prospects.

3. Stereoselective synthesis of α-glycosyl azides: allyl glycosyl sulfones as radical precursors.

4. Use of Antibody–Drug Conjugates in the Early Setting of Breast Cancer.

5. Food and Drug Administration Public Workshop Summary—Addressing Challenges in Inhaled Antifungal Drug Development.

6. Global outreach and networking promotion to accelerate tropical diseases elimination.

7. Targeting the undruggables—the power of protein degraders.

8. Effects of the phosphodiesterase 2 inhibitor BI 474121 on central nervous system cyclic guanosine monophosphate concentrations: Translational studies.

9. Identifying therapeutic target genes for migraine by systematic druggable genome-wide Mendelian randomization.

10. An Extensive Analysis of Current Synthetic Methodologies and Applications of Imidazo/Benzimidazo[1,2‐c]Quinazolines.

11. Testing dilemmas in the clinic: Lessons learned from biomarker-based drug development.

12. Biomarker-Driven Oncology Trial Design and Subgroup Characterization: Challenges and Potential Solutions.

13. The necroptosis cell death pathway drives neurodegeneration in Alzheimer's disease.

14. Rapid Self‐Assembly Mini‐Livers Protect Mice Against Severe Hepatectomy‐Induced Liver Failure.

15. Defining the next generation of severe malaria treatment: a target product profile.

16. Adaptive designs were primarily used but inadequately reported in early phase drug trials.

17. Evolutionary druggability for low-dimensional fitness landscapes toward new metrics for antimicrobial applications.

18. Potential Using of Resveratrol and Its Derivatives in Medicine.

19. Pharmaceutical Emulsions: A Viable Approach for Ocular Drug Delivery.

20. The trace amine-associated receptor 1 agonists – non-dopaminergic antipsychotics or covert modulators of D2 receptors?

21. Comparison of RNA-Sequencing Methods for Degraded RNA.

22. Shedding Light on Dark Chemical Matter: The Discovery of a SARS-CoV-2 M pro Main Protease Inhibitor through Intensive Virtual Screening and In Vitro Evaluation.

23. NLRP3 Inflammasome Inhibitors for Antiepileptogenic Drug Discovery and Development.

24. The Antifungal Potential of Niclosamide and Structurally Related Salicylanilides.

25. Research on the Medicinal Chemistry and Pharmacology of Taxus × media.

26. Advances in Anti-Cancer Drug Development: Metformin as Anti-Angiogenic Supplemental Treatment for Glioblastoma.

27. D3 Receptor-Targeted Cariprazine: Insights from Lab to Bedside.

28. Small-Molecule Inhibition of CBX4/7 Hypersensitises Homologous Recombination-Impaired Cancer to Radiation by Compromising CtIP-Mediated DNA End Resection.

29. Hepatocellular Carcinoma: Beyond the Border of Advanced Stage Therapy.

30. N -Benzylated 5-Hydroxybenzothiophene-2-carboxamides as Multi-Targeted Clk/Dyrk Inhibitors and Potential Anticancer Agents.

31. GCARDTI: Drug–target interaction prediction based on a hybrid mechanism in drug SELFIES.

32. Direct visualization of ribosomes in the cell-free system revealed the functional evolution of aminoglycoside.

33. Methods for Neuroscience Drug Development: Guidance on Standardization of the Process for Defining Clinical Outcome Strategies in Clinical Trials.

34. Defeating MYC with drug combinations or dual-targeting drugs.

36. Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs.

37. Protein tyrosine phosphatase 1B in metabolic diseases and drug development.

38. Electrolytic bubble-based flow sensing using electrochemical resistance measurement in a microchannel.

39. Biomarker-guided drug development provides value for patients, payers and drug developers: lessons learned from 25 years in the biomarker industry.

40. Food‐Drug Effects and Pediatric Drug Development Studies Submitted to the US Food and Drug Administration, 2012‐2022.

41. Procyanidin C1 inhibits tumor growth and metastasis in colon cancer via modulating miR-501-3p/HIGD1A axis.

42. A deep learning based multi-model approach for predicting drug-like chemical compound's toxicity.

43. DTKGIN: Predicting drug-target interactions based on knowledge graph and intent graph.

45. TAAR1 agonist ulotaront delays gastric emptying of solids in patients with schizophrenia and concurrent metabolic syndrome with prediabetes.

46. Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double‐blind, placebo‐controlled, Phase I trial.

47. Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: A year in review.

48. Protein target similarity is positive predictor of in vitro antipathogenic activity: a drug repurposing strategy for Plasmodium falciparum.

49. Ebselen analogues delay disease onset and its course in fALS by on-target SOD-1 engagement.

50. Single nucleotide polymorphisms in the cannabinoid CB2 receptor: Molecular pharmacology and disease associations.

Catalog

Books, media, physical & digital resources